Pancreatic Cancer Clinical Trials

Find Pancreatic Cancer Clinical Trials Near You

Initial Feasibility Study to Evaluate the Safety and Efficacy of the Permanently Implantable LDR CivaSheet® in Combination With External Beam Radiation in the Treatment of Pancreatic Cancer

Who is this study for? Patients with pancreatic cancer
What treatments are being studied? Directional Brachytherapy Source Implant
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• • Subject signed inform consent

‣ Age \> 18 years

⁃ Not pregnant or breast feeding

⁃ Patient capable of undergoing anesthesia

⁃ Patient selected to undergo Whipple procedure or distal pancreatectomy

⁃ Patient does not have metastatic disease

⁃ Patients will have close margins

⁃ No prior radiation therapy to the region for separate cancer

⁃ Confirmed diagnosis of borderline resectable or locally advanced pancreatic adenocarcinoma

⁃ Patient Received neoadjuvant chemoradiation (4-10 weeks prior to surgery)

⁃ Chemotherapy was administered for 2-6 cycles with any combination of the following agents:

⁃ Gemcitabine + nb-paclitaxel

⁃ FOLFIRINOX

⁃ Neoadjuvant Chemoradiation was administered as IMRT or 3DCRT (up to 56 Gy), or SBRT (up to 36 Gy) with Pre-operative External beam dose (NCCN)

⁃ up to 56 Gy (1.8-2.0 Gy per fractions) with concurrent gemcitabine, capecitabine, or infusional 5-fluorouracil

Locations
United States
Florida
Tampa General Hospital
NOT_YET_RECRUITING
Tampa
Illinois
Rush University Cancer Center
COMPLETED
Chicago
Advocate Christ Medical Center
RECRUITING
Oak Lawn
Louisiana
University Medical Center LSU
COMPLETED
New Orleans
Pennsylvania
Fox Chase Cancer Center
COMPLETED
Philadelphia
Virginia
Virginia Commonwealth University Massey Cancer Center
COMPLETED
Richmond
Contact Information
Primary
Carra Castagnero
ccastagnero@civatechoncology.com
919-314-5515
Backup
Kristy Perez, PhD
kperez@civatechoncology.com
9193145515
Time Frame
Start Date: 2017-05-31
Estimated Completion Date: 2028-10-30
Participants
Target number of participants: 80
Treatments
Experimental: Directional Brachytherapy Source Implant
Patients undergoing a pancreatic cancer resection will receive a CivaSheet LDR directional brachytherapy implant at the time of surgery. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
Related Therapeutic Areas
Sponsors
Leads: CivaTech Oncology

This content was sourced from clinicaltrials.gov